Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2011 Dec;85(6):1015-24.
doi: 10.4269/ajtmh.2011.11-0464.

Review: Malaria chemoprophylaxis for travelers to Latin America

Affiliations
Review

Review: Malaria chemoprophylaxis for travelers to Latin America

Laura C Steinhardt et al. Am J Trop Med Hyg. 2011 Dec.

Abstract

Because of recent declining malaria transmission in Latin America, some authorities have recommended against chemoprophylaxis for most travelers to this region. However, the predominant parasite species in Latin America, Plasmodium vivax, can form hypnozoites sequestered in the liver, causing malaria relapses. Additionally, new evidence shows the potential severity of vivax infections, warranting continued consideration of prophylaxis for travel to Latin America. Individualized travel risk assessments are recommended and should consider travel locations, type, length, and season, as well as probability of itinerary changes. Travel recommendations might include no precautions, mosquito avoidance only, or mosquito avoidance and chemoprophylaxis. There are a range of good options for chemoprophylaxis in Latin America, including atovaquone-proguanil, doxycycline, mefloquine, and--in selected areas--chloroquine. Primaquine should be strongly considered for nonpregnant, G6PD-nondeficient patients traveling to vivax-endemic areas of Latin America, and it has the added benefit of being the only drug to protect against malaria relapses.

PubMed Disclaimer

Figures

Box 1.
Box 1.
Examples of chemoprophylaxis recommendations for a hypothetical traveler: selected destinations in Latin America
Box 2.
Box 2.
Recommended malaria travel advice for Latin America: considerations for health care providers

Comment in

Similar articles

Cited by

References

    1. Guerra CA, Howes RE, Patil AP, Gething PW, Van Boeckel TP, Temperley WH, Kabaria CW, Tatem AJ, Manh BH, Elyazar IR, Baird JK, Snow RW, Hay SI. The international limits and population at risk of Plasmodium vivax transmission in 2009. PLoS Negl Trop Dis. 2010;4:e774. - PMC - PubMed
    1. Mueller I, Galinski MR, Baird JK, Carlton JM, Kochar DK, Alonso PL, del Portillo HA. Key gaps in the knowledge of Plasmodium vivax, a neglected human malaria parasite. Lancet Infect Dis. 2009;9:555–566. - PubMed
    1. The World Health Organization . The World Malaria Report 2010. Geneva: WHO; 2010.
    1. Mali S, Steele S, Slutsker L, Arguin PM. Malaria surveillance–United States, 2008. MMWR Surveill Summ. 2010;59:1–15. - PubMed
    1. Price RN, Tjitra E, Guerra CA, Yeung S, White NJ, Anstey NM. Vivax malaria: neglected and not benign. Am J Trop Med Hyg. 2007;77:79–87. - PMC - PubMed